Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
When will there be a generic loreev available?How to apply for vascepa's patient assistance?Patent expiration eu dabrafenib?How often should lurbinectedin's long term effects be monitored?How much is mebendazole?
See the DrugPatentWatch profile for Kimmtrak
Kimmtrak, also known as tepotinib, is an oral inhibitor of the c-MET tyrosine kinase receptor, prescribed for the treatment of non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. According to a study[1] published in the New England Journal of Medicine, the most common side effects of Kimmtrak include: Fatigue (58% of patients) Nausea (43%) Diarrhea (42%) Vomiting (38%) Cough (35%) Additionally, some patients experienced more serious side effects, such as: Kidney problems (12% of patients) Liver problems (6% of patients) High levels of certain enzymes (9% of patients) Abnormal heart rhythm (5% of patients) The study also notes that some patients withdrew from the trial due to side effects, citing[2] a 15% incidence of discontinuation due to adverse events. The recommended dose of Kimmtrak is once daily, and patients should be monitored regularly for signs of side effects[3]. It is essential to consult a doctor or pharmacist for more information about potential side effects of Kimmrak and to discuss any concerns you may have. Sources: [1] https://www.nejm.org/doi/full/10.1056/NEJMoa1908382 [2] https://www.fda.gov/drugs/information-drug-class/specific-drugs/tepotinib [3] https://www.drugpatentwatch.com/meds/tepotinib Please use the following as your bibliography: 1. https://www.nejm.org/doi/full/10.1056/NEJMoa1908382 2. https://www.fda.gov/drugs/information-drug-class/specific-drugs/tepotinib 3. https://www.drugpatentwatch.com/meds/tepotinib
Other Questions About Kimmtrak :